University of North Carolina, Lineberger Comprehensive Cancer Center | Strategic Alliance Partners

June 22, 2016

Lisa A. Carey, MD, comments on the recent I-SPY 2 and KRISTINE findings, the I-SPY 2 program as a whole, and the work ahead in the neoadjuvant landscape of HER2-positive breast cancer.

November 24, 2015

The primary analysis of the phase III CALGB 40601 trial found that pathologic complete response to dual HER2 blockade was not statistically higher than anti-HER2 monotherapy. However, there was a high level of intertumoral heterogeneity, and patients with the HER2-enriched subtype had a high pCR with both single and dual anti-HER2 therapy.

September 29, 2015

Jason Matney, PhD, clinical assistant professor, Physics and Computing Division, Department of Radiation Oncology, UNC School of Medicine, discusses a prospective assessment of deep inspiration breath hold to prevent radiation-associated cardiac perfusion defects in patients with left-sided breast cancer.

September 08, 2015

Juneko Grilley-Olson, MD, assistant professor, UNC-Chapel Hill, Clinical Research, Thoracic Oncology Program, Head and Neck Oncology Program, Bone and Soft Tissue Oncology Program, UNC Lineberger Comprehensive Cancer Center, discusses treating patients with cancer based on their molecular profile.

August 11, 2015

Peter Voorhees, MD, UNC Lineberger Comprehensive Cancer Center, discusses the future treatment paradigm for myeloma.

May 08, 2015

In an interview with OncLive, Charles M. Perou, MD, explains the importance of understanding and treating each subtype differently and why oncologists should be aware of the similarities between basal-like breast cancer and other non-breast cancer tumor types.

April 14, 2015

Gary L. Johnson, PhD, discusses how BET bromodomain inhibitors could offer a potential solution to lapatinib resistance in patients with HER2-postive breast cancer.

March 05, 2015

OncLive spoke with Lisa A. Carey, MD, professor at the University of North Carolina Chapel Hill, about recent developments for patients with triple-negative breast cancer.

July 08, 2014

North Carolina's only public NCI-designated comprehensive cancer center will work with OncLive to educate the oncology community on ongoing cancer prevention, treatment, and research programs.

June 13, 2014

Charles M. Perou, PhD, discusses a trial (CALGB 40601) presented at the 2014 ASCO Annual Meeting that analyzed gene expression signatures in patients with HER2-positive breast cancer treated with weekly paclitaxel and trastuzumab with or without lapatinib.

May 12, 2014

Hyman B. Muss, MD, professor of oncology, University of North Carolina, director, Geriatric Oncology, Lineberger Comprehensive Cancer Center, discusses evaluating cardiac toxicity in patients with breast cancer.

April 03, 2014

Hyman B. Muss, MD, professor of oncology, University of North Carolina, director, Geriatric Oncology, Lineberger Comprehensive Cancer Center, discusses maximizing cardiac function in patients with breast cancer.

March 27, 2014

The FDA's Molecular and Clinical Genetics advisory committee has unanimously supported the safety, efficacy, and positive risk-benefit profile of the noninvasive stool-based DNA test Cologuard in a 10-0 vote.

January 15, 2014

Poor nutritional status-specifically, a low level of serum albumin-is a predictor of complications following radical cystectomy for patients with bladder cancer

July 17, 2013

Albert S. Baldwin, Jr, PhD, focuses on understanding the regulation and biological functions of NF-κB and its role in disease, particularly in cancer, in a laboratory he heads at the UNC Lineberger Comprehensive Cancer Center.

May 24, 2013

Breast cancer clinicians today are faced with an ever-expanding number of older patients, yet determining the most appropriate treatment for these individuals can be challenging.

May 02, 2013

Lisa A. Carey, MD, Professor of Medicine, University of North Carolina at Chapel Hill, discusses the present and future state of clinical trial design.

April 17, 2013

Clinical trials are under way that may change the way risk of recurrence is assessed for early-stage breast cancer patients, allowing for individualization of therapy.

April 05, 2013

Lisa A. Carey, MD, Professor of Medicine, University of North Carolina at Chapel Hill, discusses the use of everolimus in the metastatic and adjuvant settings of breast cancer.

April 03, 2013

Hyman B. Muss, MD, Professor of Medicine, Director of Geriatric Oncology, Division of Hematology and Oncology, Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill School of Medicine, discusses the need for a team environment when treating an older patient.